SAR-413792

N/A

Report date: 2025/01/26 17:57:53
NME

Base Information

Drug NameSAR-413792
Drug Alias Namepan-pim1/2 kinase inhibitor (AbbVie/Rakuten Medical/TME Therapeutics/Qiagen/BMS)pan-pim kinases inhibitors (Sanofi)SAR-413792
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProto-oncogene serine/threonine-protein kinase Pim-1 inhibitorsSerine/threonine-protein kinase pim-2 inhibitors
TargetsSerine/threonine-protein kinase pim-2Proto-oncogene serine/threonine-protein kinase Pim-1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesTME Therapeutics LLCQiagen NVRakuten Medical Inc +[6] 
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A